Table 5 Immunophenotypic alterations detected in PB monocytes from LR-MDS patients versus normal individuals (controls)

 CD14⁺CD56⁺ cells (% total CD14⁺ monocytes) (*)

 Increased percentages of CD14⁺ 56⁺ cells (>  18.0% total CD14⁺ monocytes)

  Mild: CD56⁺ cells]18%–23%]

  Moderate: CD56⁺ cells [23%–28%]

  Severe: CD56⁺ cells]28%–100%]

 CD14⁺CD16⁺ cells (% total CD14⁺ monocytes) (**)

 Decreased percentages of CD14⁺CD16⁺ cells (<  5.0% of total CD14⁺ monocytes)

  Mild: CD16⁺ cells [2.5%–5.0%]

  Moderate: CD16⁺ cells [1.25–2.5%]

  Severe: CD16⁺ cells [0.00–1.25%]